Grifols SA stock forecast
Grifols SA (G0FB) Stock Forecast & Price Target
G0FB Analyst Ratings
G0FB Stock 12 Month Forecast
Average Price Target
€8.06▲(3.31% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Sophia Graeff Buhl-Nielsen | J.P. Morgan | €8.95→€8.06 | hold | 3.31%Upside | Assigned | 10/26/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Sophia Graeff Buhl-NielsenJ.P. Morgan | HoldAssigned€8.95→€8.06 | 10/26/26 | 3.31%Upside |
Best Analysts Covering Grifols SA
Copying PerPlexity Drug Manufacturers - General's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +0.14% per trade.
Copying PerPlexity Drug Manufacturers - General's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -2.02% per trade.
Copying PerPlexity Drug Manufacturers - General's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -2.02% per trade.
G0FB Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 1 | 1 |
In the current month, G0FB has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. G0FB average Analyst price target in the past 3 months is 8.06.
G0FB Financial Forecast
G0FB Earnings Forecast
Next quarter’s earnings estimate for G0FB is EUR 0.30 with a range of EUR 0.30 to EUR 0.30. The previous quarter’s EPS was EUR 0.25. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
G0FB Sales Forecast
Next quarter’s sales forecast for G0FB is EUR 2.07B with a range of EUR 2.07B to EUR 2.07B. The previous quarter’s sales results were EUR 2.10B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

